| Nov 15 |
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
|
| Nov 14 |
Immutep stock jumps 11% on positive data for eftilagimod alpha
|
| Nov 14 |
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
|
| Nov 14 |
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
|
| Nov 14 |
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
|
| Nov 6 |
Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago
|
| Oct 29 |
Immutep Quarterly Activities Report Q1 FY25
|
| Oct 28 |
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
|
| Oct 17 |
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
|
| Oct 10 |
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
|
